A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single Dose Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer (Protocol SPI-611)

Trial Profile

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single Dose Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer (Protocol SPI-611)

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Apaziquone (Primary)
  • Indications Bladder cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 10 May 2016 Results of an integrated analysis from SPI-611 and SPI-612 trials presented at the 111th Annual Meeting of the American Urological Association
    • 10 May 2016 Results of two phase III studies presented at the 111th Annual Meeting of the American Urological Association
    • 06 May 2016 According to a Spectrum Pharmaceuticals media release, data from this and another phase III trial (SPI-612) will be presented at the American Urological Association Education and Research Inc.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top